Intravitreal Fluocinolone Acetonide Implant (ILUVIEN ® ) for the Treatment of Retinal Conditions. A Review of Clinical Studies.
Yusuf MushtaqMaryam M MushtaqZisis GatzioufasMatteo RipaLorenzo MottaGeorgios D PanosPublished in: Drug design, development and therapy (2023)
Fluocinolone acetonide (FAc) intravitreal implant (Iluvien ® ) is a corticosteroid implant indicated for the treatment of diabetic macular oedema (DMO) in patients who have previously received conventional treatment without good response, non-infectious posterior uveitis, and as an off-label treatment of the macular oedema secondary to retinal vein occlusion. FAc is a non-biodegradable 0.19 mg intravitreal implant which is designed to release FAc over 3 years at a rate of approximately 0.2 mcg per day. The aim of this review is to describe the special pharmacological properties of Iluvien and display the outcomes of the most important clinical trials and real-world studies regarding its efficacy and safety for the management of the above retinal disorders.
Keyphrases
- diabetic retinopathy
- optical coherence tomography
- clinical trial
- vascular endothelial growth factor
- end stage renal disease
- randomized controlled trial
- type diabetes
- chronic kidney disease
- ejection fraction
- drug delivery
- age related macular degeneration
- rheumatoid arthritis
- endothelial cells
- prognostic factors
- replacement therapy
- insulin resistance